Concepedia

Jeremy Findlay

JF

Statistics

Publications

12

Citations

397

H-Index

12

Active since

1992

Affiliations

Eli Lilly (United Kingdom)(Current)

Eli Lilly (United States)

Jeremy Findlay is an author at Eli Lilly (United Kingdom) specializing in neuropharmacology, pharmacology, and drug discovery.

Publications per year

1992–2017

12

Publications

12

Duloxetine (Cymbalta™), a dual inhibitor of serotonin and norepinephrine reuptake

F.P. Bymaster, E. E. Beedle, Jeremy Findlay et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 123 citations · Full text

, , +14

1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors

Christopher D. Beadle, John R. Boot, Nicholas P. Camp et al. · Bioorganic & Medicinal Chemistry Letters · 2005 · 41 citations · Full text

, , +7

ω-Agatoxin IVA identifies a single calcium channel subtype which contributes to the potassium-induced release of acetylcholine, 5-hydroxytryptamine, dopamine, γ-aminobutyric acid and glutamate from rat brain slices

Janette Harvey, Susan Wedley, Jeremy Findlay et al. · Neuropharmacology · 1996 · 40 citations

, , +17

Pharmacological profiling of native group II metabotropic glutamate receptors in primary cortical neuronal cultures using a FLIPR

Helen Sanger, Lydia Hanna, Ellen M. Colvin et al. · Neuropharmacology · 2012 · 30 citations

, , +14

Discovery and structure–activity relationships of novel selective norepinephrine and dual serotonin/norepinephrine reuptake inhibitors

John R. Boot, Manuel Cases, Barry P. Clark et al. · Bioorganic & Medicinal Chemistry Letters · 2004 · 30 citations

, , +16

1–5 of 12